| Primary |
| Breast Cancer |
22.2% |
| Antiemetic Supportive Care |
20.0% |
| Drug Use For Unknown Indication |
20.0% |
| Product Used For Unknown Indication |
15.6% |
| Chronic Lymphocytic Leukaemia |
8.9% |
| Nausea |
4.4% |
| Colorectal Cancer |
2.2% |
| Myelodysplastic Syndrome |
2.2% |
| Prophylaxis Of Nausea And Vomiting |
2.2% |
| Unevaluable Event |
2.2% |
|
| Thrombosis |
21.4% |
| Biliary Colic |
10.7% |
| Vomiting |
10.7% |
| Neutropenia |
7.1% |
| Pulmonary Embolism |
7.1% |
| Pulmonary Sepsis |
7.1% |
| Restlessness |
7.1% |
| Syncope |
7.1% |
| White Blood Cell Count Decreased |
7.1% |
| Optic Ischaemic Neuropathy |
3.6% |
| Pacemaker Complication |
3.6% |
| Pancytopenia |
3.6% |
| Pulmonary Fibrosis |
3.6% |
|
| Secondary |
| Prophylaxis Of Nausea And Vomiting |
12.6% |
| Prophylaxis |
11.1% |
| Bronchial Carcinoma |
8.9% |
| Drug Use For Unknown Indication |
8.9% |
| Breast Cancer |
8.1% |
| Hypertension |
6.7% |
| Acute Lymphocytic Leukaemia |
5.9% |
| Chronic Lymphocytic Leukaemia |
5.9% |
| B-cell Lymphoma |
4.4% |
| Hodgkin's Disease |
4.4% |
| Lymphoma |
3.7% |
| Convulsion |
3.0% |
| Antiemetic Supportive Care |
2.2% |
| Antifungal Prophylaxis |
2.2% |
| Electrolyte Substitution Therapy |
2.2% |
| Myelodysplastic Syndrome |
2.2% |
| Sleep Disorder |
2.2% |
| Vomiting |
2.2% |
| Antibiotic Therapy |
1.5% |
| Breast Cancer Metastatic |
1.5% |
|
| Neutropenia |
12.5% |
| Optic Ischaemic Neuropathy |
12.5% |
| Thrombosis |
12.5% |
| White Blood Cell Count Decreased |
12.5% |
| Toxic Epidermal Necrolysis |
8.3% |
| Febrile Neutropenia |
4.2% |
| Pancreatic Enzymes Increased |
4.2% |
| Pancytopenia |
4.2% |
| Restlessness |
4.2% |
| Sepsis |
4.2% |
| Stevens-johnson Syndrome |
4.2% |
| Stomatitis |
4.2% |
| Thrombosis In Device |
4.2% |
| Transaminases Increased |
4.2% |
| Vomiting |
4.2% |
|
| Concomitant |
| Colorectal Cancer |
21.3% |
| Drug Use For Unknown Indication |
12.1% |
| Vomiting |
11.2% |
| Premedication |
8.2% |
| Product Used For Unknown Indication |
6.5% |
| Breast Cancer |
6.1% |
| Prophylaxis |
5.7% |
| Nausea |
4.6% |
| Pain |
4.0% |
| Non-small Cell Lung Cancer |
3.0% |
| Colorectal Cancer Metastatic |
2.4% |
| Acute Myeloid Leukaemia |
2.1% |
| Hypertension |
2.0% |
| Infection |
1.8% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Prostate Cancer |
1.6% |
| Breast Cancer Metastatic |
1.5% |
| Rectal Cancer |
1.4% |
| Insomnia |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
|
| Pulmonary Embolism |
10.6% |
| Pyrexia |
10.1% |
| Vomiting |
8.9% |
| Sepsis |
7.3% |
| Leukopenia |
6.1% |
| Renal Failure Acute |
6.1% |
| Narcotic Intoxication |
5.6% |
| Pleural Effusion |
5.0% |
| General Physical Health Deterioration |
4.5% |
| Neutropenia |
4.5% |
| Weight Decreased |
3.9% |
| Febrile Neutropenia |
3.4% |
| Haemolysis |
3.4% |
| Infection |
3.4% |
| Pulmonary Oedema |
3.4% |
| Cardiovascular Disorder |
2.8% |
| Pneumonia |
2.8% |
| Respiratory Failure |
2.8% |
| Stomatitis |
2.8% |
| Urinary Incontinence |
2.8% |
|
| Interacting |
| Mds |
50.0% |
| Nausea Prophylaxis |
50.0% |
|
| Optic Ischaemic Neuropathy |
100.0% |
|
